Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: Barbara Bullard who wrote (838)	2/26/1999 10:35:00 PM
From: JF Quinnelly	Read Replies (1) \| Respond to of 1728

T/A will only tell you that the stock has been strong, it won't tell you why. It means that no one is eager to unload the stock, and that ought to include those with a close view of how the gene chip market is developing. I spotted an article in Electronic News this week about how Motorola is setting up a biochip division. They think the mass marketing of genetic chips is still 5-10 years away, but they expect it to be big and they intend to participate. Affymetrix was mentioned in the article as the leader in the field. Hyseq was also mentioned as a player. A continuing slide in the market could drag down AFFX, as margin players can be forced out of all their positions, and some people will sell in response to broader market averages. If we see the 20s any time soon I'll buy some more.